This paper outlines why it’s especially challenging to design clinical trials for rare disease therapies. It describes key considerations regarding:
- Defining the patient population for a clinical program
- Selecting endpoints
- Selecting comparator(s)
- Defining cohort sizes
This paper is part 2 in an ongoing series. Part 1 can be downloaded here.